Pyr-T

Pyr-T
Names
Preferred IUPAC name
3-[2-(Pyrrolidin-1-yl)ethyl]-1H-indole
Other names
N,N-Tetramethylenetryptamine
Identifiers
CAS Number
3D model (JSmol)
ChemSpider
PubChem CID
UNII
InChI
  • InChI=1S/C14H18N2/c1-2-6-14-13(5-1)12(11-15-14)7-10-16-8-3-4-9-16/h1-2,5-6,11,15H,3-4,7-10H2 checkY
    Key: CVTZCBLFHNGYDQ-UHFFFAOYSA-N checkY
  • InChI=1/C14H18N2/c1-2-6-14-13(5-1)12(11-15-14)7-10-16-8-3-4-9-16/h1-2,5-6,11,15H,3-4,7-10H2
    Key: CVTZCBLFHNGYDQ-UHFFFAOYAE
SMILES
  • c2c(c1ccccc1[nH]2)CCN3CCCC3
Properties
Chemical formula
 C14H18N2
Molar mass 214.312 g·mol−1
Melting point 193 to 194 °C (379 to 381 °F; 466 to 467 K) (HCl salt.)
Boiling point 170 to 180 °C (338 to 356 °F; 443 to 453 K) (Freebase at 0.05mm/Hg.)
log P 2.74410
Vapor pressure 1.02x10−5mmHg
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)
Infobox references

Pyr-T (N,N-tetramethylenetryptamine) is a lesser-known, possible psychedelic drug. Pyr-T was first characterized by S. Mitzal.[1] Toxicity testing was later performed by Hunt and Brimblecombe, and although a lethal dosage was found in rats, a value is not given.[2] In the book TiHKAL (Tryptamines I Have Known and Loved), neither the dosage nor the duration are reported.[3][4]

Pyr-T produces few to no effects in humans, but some behavioral changes were observed in animal tests.[2] Very little data exists about the pharmacological properties, metabolism, and toxicity of pyr-T.

See also

References

  1. ↑ Mitzal, S. (1962). "N/A". Dissertationes Pharm. 14: 305.
  2. 1 2 Hunt, R. R.; Brimblecombe, R. W. (July 1967). "Synthesis and Biological Activity of Some Ring-Substituted Tryptamines". Journal of Medicinal Chemistry. 10 (4): 646–648. doi:10.1021/jm00316a027. PMID 4962512.
  3. ↑ Shulgin, Alexander; Shulgin, Ann (1997). TiHKAL, The Continuation (1st ed.). Berkeley, CA, USA: Transform Press. pp. 577–578. ISBN 0-9630096-9-9. Retrieved 7 April 2018.
  4. ↑ Krasowski MD, Ekins S. Using cheminformatics to predict cross reactivity of “designer drugs” to their currently available immunoassays. J Cheminform 6, 22 (2014). doi:10.1186/1758-2946-6-22


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.